Stockscreener 앱 받기
26.42
6.49%
1.61
전일 마감가:
$24.81
열려 있는:
$24.9
하루 거래량:
3.68M
Relative Volume:
2.08
시가총액:
$4.63B
수익:
-
순이익/손실:
$-382.71M
주가수익비율:
-10.08
EPS:
-2.62
순현금흐름:
$-325.64M
1주 성능:
+15.67%
1개월 성능:
+12.71%
6개월 성능:
+65.75%
1년 성능:
-4.24%
1일 변동 폭
$24.46
$26.50
1주일 범위
$22.33
$27.06
52주 변동 폭
$12.72
$28.08
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
26.42 | 4.35B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
EPS Watch: Why OrthoPediatrics Corp. stock appeals to dividend seekersWeekly Stock Report & Low Drawdown Trading Strategies - moha.gov.vn
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com
Immunovant Raises $550 Million Through Stock Offering - TipRanks
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha
Immunovant Enters Underwriting Agreement for Stock Offering - TradingView — Track All Markets
Immunovant (NASDAQ:IMVT) Stock Price Up 8.1%Here's Why - MarketBeat
Immunovant, Inc. $IMVT is Armistice Capital LLC's 9th Largest Position - MarketBeat
Immunovant drops 7%, prices $550M stock offering - MSN
Immunovant announces $550 million stock offering - MSN
Latham & Watkins Advises on Immunovant’s US$550 Million Offering of Common Stock - Latham & Watkins LLP
Immunovant announces $550 million stock offering and clinical program updates - Investing.com Canada
HighVista Strategies LLC Buys 87,160 Shares of Immunovant, Inc. $IMVT - MarketBeat
Immunovant announces $550 million stock offering and clinical program updates By Investing.com - Investing.com South Africa
Immunovant Announces $550 Million Stock Offering - TipRanks
Immunovant announces pricing of $550 million common stock financing - marketscreener.com
Immunovant Announces Pricing Of $550 Million Common Stock Financing - TradingView — Track All Markets
Immunovant Prices $550 Million Stock Offering - marketscreener.com
Immunovant Announces Pricing of $550 Million Common Stock Financing - The Globe and Mail
Immunovant (Nasdaq: IMVT) raises $550M to support potential IMVT-1402 Graves’ launch - Stock Titan
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Norges Bank Buys Shares of 687,662 Immunovant, Inc. $IMVT - MarketBeat
55,524 Shares in Immunovant, Inc. $IMVT Purchased by Capital Fund Management S.A. - MarketBeat
Two Seas Capital LP Boosts Stake in Immunovant, Inc. $IMVT - MarketBeat
Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells 15,000 Shares of Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells 22,249 Shares of Stock - MarketBeat
Immunovant Executives Sell Shares Under Trading Plans - TradingView
Dir Fromkin Surrenders 22,249 Of Immunovant Inc [IMVT] - TradingView
Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Yahoo Finance
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - MSN
Immunovant (IMVT) Stock Analysis Report | Financials & Insights - Benzinga
XTX Topco Ltd Buys New Holdings in Immunovant, Inc. $IMVT - MarketBeat
Tejara Capital Ltd Raises Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. $IMVT Shares Acquired by Geode Capital Management LLC - MarketBeat
(IMVT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
12 Best Short Squeeze Stocks to Buy Right Now - Insider Monkey
Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength - MSN
Officer Geffner Files To Sell 50,000 Of Immunovant Inc [IMVT] - TradingView
Officer Geffner Files To Sell 103,897 Of Immunovant Inc [IMVT] - TradingView
Immunovant (IMVT): Assessing Valuation Following R&D Leadership Restructuring and CMO Departure - Sahm
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - MSN
Have Insiders Sold Immunovant Shares Recently? - simplywall.st
Immunovant Restructures R&D Leadership with CMO Departure - The Globe and Mail
Immunovant COO Gloria sells $298k in shares By Investing.com - Investing.com Nigeria
Immunovant COO Gloria sells $298k in shares - Investing.com
Immunovant Insider Sold Shares Worth $298,237, According to a Recent SEC Filing - MarketScreener
Immunovant COO Gloria Melanie Sells Shares to Cover Tax Obligations - TradingView
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
[8-K] Immunovant, Inc. Reports Material Event | IMVT SEC FilingForm 8-K - Stock Titan
Immunovant, Inc. Announces Cessation of Michael Geffner, M.D., M.B.A. as Chief Medical Officer, Effective November 21, 2025 - marketscreener.com
How analysts rate Immunovant Inc. stock todayInsider Selling & Technical Entry and Exit Tips - newser.com
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):